(NTRA) Natera - Ratings and Ratios

Natera, Inc. (NASDAQ:NTRA) is a leading diagnostics company specializing in molecular testing services worldwide. Its product portfolio includes Panorama, a non-invasive prenatal test (NIPT) for chromosomal abnormalities in singleton and twin pregnancies; Horizon, a carrier screening test for genetic variations; Vistara, an NIPT for 25 single-gene disorders; Spectrum, a preimplantation genetic test for IVF patients; Anora, which analyzes miscarriage tissue; Empower, a hereditary cancer screening test; and a non-invasive prenatal paternity product. The company also offers Signatera, a molecular residual disease test for cancer recurrence monitoring; Altera, a tissue-based genomic profiling test; Prospera, for assessing organ rejection in transplant patients; and Renasight, a kidney gene panel test. Additionally, Natera provides Constellation, a cloud-based software platform for data management.

Natera serves a diverse range of clients, including independent laboratories, national and regional reference laboratories, medical centers, physician practices, research institutions, and pharmaceutical companies. Its distribution network includes a direct sales force and partnerships with laboratory and distribution providers. The company has strategic collaborations with BGI Genomics Co., Ltd. for next-generation sequencing (NGS)-based genetic testing and with Foundation Medicine, Inc. for circulating tumor DNA monitoring assays. Formerly known as Gene Security Network, LLC, Natera was renamed in 2012 and is headquartered in Austin, Texas, with operations dating back to its founding in 2003.

Based on the provided and , Nateras stock (NASDAQ:NTRA) is expected to face headwinds in the next three months. The stock is trading below its 20-day and 50-day moving averages (SMA20: 145.14, SMA50: 151.28), indicating bearish momentum. The average true range (ATR) of 8.34 suggests moderate volatility, with potential price swings of 8-10% over the period. From a perspective, the companys high price-to-book (P/B) ratio of 16.74 and price-to-sales (P/S) ratio of 11.79 indicate rich valuations, which could lead to a correction. The negative return on equity (RoE) of -15.93% further raises concerns about profitability. Overall, NTRA is likely to remain under pressure, with a potential downside target near $130, barring significant positive catalysts.